Business
Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects
Novel Protocol is Expected to be Less Painful with Efficacy Similar to Conventional PDTWOBURN, MA / ACCESSWIRE / May 15, 2023 / Biofrontera Inc. (Nasdaq:BFRI)
About this update from Biofrontera Inc.
[{"type":"text","content":"Novel Protocol is Expected to be Less Painful with Efficacy Similar to Conventional PDTWOBURN, MA / ACCESSWIRE / May 15, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the \"Company\"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that the U.S. Patent and Trademark Office (USPTO) has granted a new patent to Biofrontera Bioscience GmbH related to a photodynamic therapy (PDT) protocol that is expected to be less painful but similarly effective to conventional PDT. This new patent is exclusively licensed to Biofrontera Inc. and expires in April 2039, including a patent term adjustment (PTA) approved by the USPTO.Titled \"Photodynamic therapy comprising two light exposures at different wavelengths\" (U.S. Patent No. 11,642,411 B2), the patent covers the use of a composition comprising a photosensitizer, a light-sensitive molecule activated by the absorption of light, that is used in PDT performed with illumination by two different photo-activating wavelengths of light.\"This is the fourth US patent recently issued to Biofrontera Bioscience GmbH and licensed exclusively to Biofrontera Inc. At the start of 2022 we had no protection for our intellectual property in the U.S., and since then we were granted protection for our product combination of Ameluz and the RhodoLED lamp series until 2040. Our growing licensed patent portfolio further establishes Biofrontera not only as a leader in PDT, but also in dermatologic innovation,\" said Hermann Lübbert, Executive Chairman of Biofrontera Inc. and the sole inventor on the patent. \"This latest patent covers a protocol that supports further adoption of PDT. With an incubation between application of the gel with exposure to light with a wavelength spectrum similar to sunlight followed by 10 minutes of red-light illumination, this novel protocol is far more patient-friendly yet similarly effective to conventional PDT. It adds additional patient friendliness to another patent granted early in 2022, protecting red light application in defined ramps and pulses, expected to reduce PDT pain even further. Both patents add substance to our goal of providing doctors with data on patient-friendly PDT protocols to help them select the optimal risk-benefit ratio for their patients.\"One of the four patents granted in 2022 is already listed in FDA's Orange ...